Incremental increase in VEGFR1 + hematopoietic progenitor cells and VEGFR2 + endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients

Research output: Contribution to journalArticle

Sarika Jain, Maureen M. Ward, Jennifer O'Loughlin, Marissa Boeck, Naomi Wiener, Ellen Chuang, Tessa Cigler, Anne Moore, Diana Donovan, Christina Lam, Marta V. Cobham, Sarah Schneider, Paul Christos, Rebecca N. Baergen, Alexander Swistel, Maureen E. Lane, Vivek Mittal, Shahin Rafii, Linda T. Vahdat

Animal models have demonstrated the critical role of bone marrow-derived VEGFR1 + hematopoietic progenitor cells (HPCs) and VEGFR2 + endothelial progenitor cells (EPCs) in metastatic progression. We explored whether these cells could predict relapse and response in breast cancer (BC) patients. One hundred and thirty-two patients with stages 1-4 BC were enrolled on 2 studies. Circulating CD45 +/CD34 +/VEGFR1 + HPCs and CD45 dim/CD133 +/VEGFR2 + EPCs were assessed from peripheral blood mononuclear cells using flow cytometry. Changes in HPCs and EPCs were analyzed in (1) patients without overt disease that relapsed and (2) metastatic patients according to response by RECIST. At study entry, 102 patients were without evidence of disease and 30 patients had metastatic BC. Seven patients without evidence of BC by exam, labs, and imaging developed recurrence while on study. Median HPC/ml (range) increased from 645.8 (23.5-1,914) to 2,899 (1,176-37,336), P = 0.016, followed by an increase in median EPC/ml from 21.3 (4.7-42.5) to 94.7 (28.2-201.3), P = 0.016, prior to clinical relapse. In metastatic patients with progressive disease, median HPC/ml increased from 1,696 (10-16,470) to 5,124 (374-77,605), P = 0.0009, and median EPC/ml increased from 26 (0-560) to 71 (0-615) prior to progression, P = 0.10. In patients with responding disease, median HPC/ml decreased from 6,147 (912-85,070) to 633 (47-18,065), P = 0.05, and EPC/ml decreased from 46 (0-197) to 23 (0-105), P = 0.41, at response. There were no significant changes in these cells over time in patients with stable disease. Circulating bone marrow-derived HPCs and EPCs predict relapse and disease progression in BC patients.

Original languageEnglish
Pages (from-to)235-242
Number of pages8
JournalBreast Cancer Research and Treatment
Volume132
Issue number1
DOIs
StatePublished - Feb 1 2012

PMID: 22160642

Altmetrics

Cite this

Standard

Incremental increase in VEGFR1 + hematopoietic progenitor cells and VEGFR2 + endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients. / Jain, Sarika; Ward, Maureen M.; O'Loughlin, Jennifer; Boeck, Marissa; Wiener, Naomi; Chuang, Ellen; Cigler, Tessa; Moore, Anne; Donovan, Diana; Lam, Christina; Cobham, Marta V.; Schneider, Sarah; Christos, Paul; Baergen, Rebecca N.; Swistel, Alexander; Lane, Maureen E.; Mittal, Vivek; Rafii, Shahin; Vahdat, Linda T.

In: Breast Cancer Research and Treatment, Vol. 132, No. 1, 01.02.2012, p. 235-242.

Research output: Contribution to journalArticle

Harvard

Jain, S, Ward, MM, O'Loughlin, J, Boeck, M, Wiener, N, Chuang, E, Cigler, T, Moore, A, Donovan, D, Lam, C, Cobham, MV, Schneider, S, Christos, P, Baergen, RN, Swistel, A, Lane, ME, Mittal, V, Rafii, S & Vahdat, LT 2012, 'Incremental increase in VEGFR1 + hematopoietic progenitor cells and VEGFR2 + endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients' Breast Cancer Research and Treatment, vol. 132, no. 1, pp. 235-242. https://doi.org/10.1007/s10549-011-1906-3

APA

Jain, S., Ward, M. M., O'Loughlin, J., Boeck, M., Wiener, N., Chuang, E., ... Vahdat, L. T. (2012). Incremental increase in VEGFR1 + hematopoietic progenitor cells and VEGFR2 + endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients. Breast Cancer Research and Treatment, 132(1), 235-242. https://doi.org/10.1007/s10549-011-1906-3

Vancouver

Jain S, Ward MM, O'Loughlin J, Boeck M, Wiener N, Chuang E et al. Incremental increase in VEGFR1 + hematopoietic progenitor cells and VEGFR2 + endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients. Breast Cancer Research and Treatment. 2012 Feb 1;132(1):235-242. https://doi.org/10.1007/s10549-011-1906-3

Author

Jain, Sarika ; Ward, Maureen M. ; O'Loughlin, Jennifer ; Boeck, Marissa ; Wiener, Naomi ; Chuang, Ellen ; Cigler, Tessa ; Moore, Anne ; Donovan, Diana ; Lam, Christina ; Cobham, Marta V. ; Schneider, Sarah ; Christos, Paul ; Baergen, Rebecca N. ; Swistel, Alexander ; Lane, Maureen E. ; Mittal, Vivek ; Rafii, Shahin ; Vahdat, Linda T. / Incremental increase in VEGFR1 + hematopoietic progenitor cells and VEGFR2 + endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients. In: Breast Cancer Research and Treatment. 2012 ; Vol. 132, No. 1. pp. 235-242.

BibTeX

@article{ca3bd4a4d0fa4adfb8c2363584e00195,
title = "Incremental increase in VEGFR1 + hematopoietic progenitor cells and VEGFR2 + endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients",
abstract = "Animal models have demonstrated the critical role of bone marrow-derived VEGFR1 + hematopoietic progenitor cells (HPCs) and VEGFR2 + endothelial progenitor cells (EPCs) in metastatic progression. We explored whether these cells could predict relapse and response in breast cancer (BC) patients. One hundred and thirty-two patients with stages 1-4 BC were enrolled on 2 studies. Circulating CD45 +/CD34 +/VEGFR1 + HPCs and CD45 dim/CD133 +/VEGFR2 + EPCs were assessed from peripheral blood mononuclear cells using flow cytometry. Changes in HPCs and EPCs were analyzed in (1) patients without overt disease that relapsed and (2) metastatic patients according to response by RECIST. At study entry, 102 patients were without evidence of disease and 30 patients had metastatic BC. Seven patients without evidence of BC by exam, labs, and imaging developed recurrence while on study. Median HPC/ml (range) increased from 645.8 (23.5-1,914) to 2,899 (1,176-37,336), P = 0.016, followed by an increase in median EPC/ml from 21.3 (4.7-42.5) to 94.7 (28.2-201.3), P = 0.016, prior to clinical relapse. In metastatic patients with progressive disease, median HPC/ml increased from 1,696 (10-16,470) to 5,124 (374-77,605), P = 0.0009, and median EPC/ml increased from 26 (0-560) to 71 (0-615) prior to progression, P = 0.10. In patients with responding disease, median HPC/ml decreased from 6,147 (912-85,070) to 633 (47-18,065), P = 0.05, and EPC/ml decreased from 46 (0-197) to 23 (0-105), P = 0.41, at response. There were no significant changes in these cells over time in patients with stable disease. Circulating bone marrow-derived HPCs and EPCs predict relapse and disease progression in BC patients.",
keywords = "Angiogenic switch, Breast cancer, Metastasis, VEGFR1, VEGFR2",
author = "Sarika Jain and Ward, {Maureen M.} and Jennifer O'Loughlin and Marissa Boeck and Naomi Wiener and Ellen Chuang and Tessa Cigler and Anne Moore and Diana Donovan and Christina Lam and Cobham, {Marta V.} and Sarah Schneider and Paul Christos and Baergen, {Rebecca N.} and Alexander Swistel and Lane, {Maureen E.} and Vivek Mittal and Shahin Rafii and Vahdat, {Linda T.}",
year = "2012",
month = "2",
day = "1",
doi = "10.1007/s10549-011-1906-3",
language = "English",
volume = "132",
pages = "235--242",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

RIS

TY - JOUR

T1 - Incremental increase in VEGFR1 + hematopoietic progenitor cells and VEGFR2 + endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients

AU - Jain, Sarika

AU - Ward, Maureen M.

AU - O'Loughlin, Jennifer

AU - Boeck, Marissa

AU - Wiener, Naomi

AU - Chuang, Ellen

AU - Cigler, Tessa

AU - Moore, Anne

AU - Donovan, Diana

AU - Lam, Christina

AU - Cobham, Marta V.

AU - Schneider, Sarah

AU - Christos, Paul

AU - Baergen, Rebecca N.

AU - Swistel, Alexander

AU - Lane, Maureen E.

AU - Mittal, Vivek

AU - Rafii, Shahin

AU - Vahdat, Linda T.

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Animal models have demonstrated the critical role of bone marrow-derived VEGFR1 + hematopoietic progenitor cells (HPCs) and VEGFR2 + endothelial progenitor cells (EPCs) in metastatic progression. We explored whether these cells could predict relapse and response in breast cancer (BC) patients. One hundred and thirty-two patients with stages 1-4 BC were enrolled on 2 studies. Circulating CD45 +/CD34 +/VEGFR1 + HPCs and CD45 dim/CD133 +/VEGFR2 + EPCs were assessed from peripheral blood mononuclear cells using flow cytometry. Changes in HPCs and EPCs were analyzed in (1) patients without overt disease that relapsed and (2) metastatic patients according to response by RECIST. At study entry, 102 patients were without evidence of disease and 30 patients had metastatic BC. Seven patients without evidence of BC by exam, labs, and imaging developed recurrence while on study. Median HPC/ml (range) increased from 645.8 (23.5-1,914) to 2,899 (1,176-37,336), P = 0.016, followed by an increase in median EPC/ml from 21.3 (4.7-42.5) to 94.7 (28.2-201.3), P = 0.016, prior to clinical relapse. In metastatic patients with progressive disease, median HPC/ml increased from 1,696 (10-16,470) to 5,124 (374-77,605), P = 0.0009, and median EPC/ml increased from 26 (0-560) to 71 (0-615) prior to progression, P = 0.10. In patients with responding disease, median HPC/ml decreased from 6,147 (912-85,070) to 633 (47-18,065), P = 0.05, and EPC/ml decreased from 46 (0-197) to 23 (0-105), P = 0.41, at response. There were no significant changes in these cells over time in patients with stable disease. Circulating bone marrow-derived HPCs and EPCs predict relapse and disease progression in BC patients.

AB - Animal models have demonstrated the critical role of bone marrow-derived VEGFR1 + hematopoietic progenitor cells (HPCs) and VEGFR2 + endothelial progenitor cells (EPCs) in metastatic progression. We explored whether these cells could predict relapse and response in breast cancer (BC) patients. One hundred and thirty-two patients with stages 1-4 BC were enrolled on 2 studies. Circulating CD45 +/CD34 +/VEGFR1 + HPCs and CD45 dim/CD133 +/VEGFR2 + EPCs were assessed from peripheral blood mononuclear cells using flow cytometry. Changes in HPCs and EPCs were analyzed in (1) patients without overt disease that relapsed and (2) metastatic patients according to response by RECIST. At study entry, 102 patients were without evidence of disease and 30 patients had metastatic BC. Seven patients without evidence of BC by exam, labs, and imaging developed recurrence while on study. Median HPC/ml (range) increased from 645.8 (23.5-1,914) to 2,899 (1,176-37,336), P = 0.016, followed by an increase in median EPC/ml from 21.3 (4.7-42.5) to 94.7 (28.2-201.3), P = 0.016, prior to clinical relapse. In metastatic patients with progressive disease, median HPC/ml increased from 1,696 (10-16,470) to 5,124 (374-77,605), P = 0.0009, and median EPC/ml increased from 26 (0-560) to 71 (0-615) prior to progression, P = 0.10. In patients with responding disease, median HPC/ml decreased from 6,147 (912-85,070) to 633 (47-18,065), P = 0.05, and EPC/ml decreased from 46 (0-197) to 23 (0-105), P = 0.41, at response. There were no significant changes in these cells over time in patients with stable disease. Circulating bone marrow-derived HPCs and EPCs predict relapse and disease progression in BC patients.

KW - Angiogenic switch

KW - Breast cancer

KW - Metastasis

KW - VEGFR1

KW - VEGFR2

UR - http://www.scopus.com/inward/record.url?scp=84857924372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857924372&partnerID=8YFLogxK

U2 - 10.1007/s10549-011-1906-3

DO - 10.1007/s10549-011-1906-3

M3 - Article

VL - 132

SP - 235

EP - 242

JO - Breast Cancer Research and Treatment

T2 - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -

ID: 3103349